Ocoxin as a complement to first line treatments in cancer

Chemotherapy and radiotherapy are the most frequent treatment for patients suffering from malignant progression of cancer. Even though new treatments are now being implemented, administration of these chemotherapeutic agents remains as the first line option in many tumor types. However, the secondary effects of these compounds represent one of the main reasons cancer patients lose life quality during disease progression. Recent data suggests that Ocoxin, a plant extract and natural compound based nutritional complement rich in antioxidants and anti-inflammatory mediators exerts a positive effect in patients receiving chemotherapy and radiotherapy. This mixture attenuates the chemotherapy and radiotherapy-related side effects such as radiation-induced skin burns and mucositis, chemotherapy-related diarrhea, hepatic toxicity and blood-infection. Moreover, it has been proven to be effective as anticancer agent in different tumor models both in vitro and in vivo, potentiating the cytotoxic effect of several chemotherapy compounds such as Lapatinib, Gemcitabine, Paclitaxel, Sorafenib and Irinotecan. The aim of this review is to put some light on the potential of this nutritional mixture as an anticancer agent and complement for the standard chemotherapy routine

Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma

Whereas the prevalence of several cancer types is decreasing, skin malignancies are growing more common every year. Malignant melanoma is the most aggressive form of skin cancer with high metastatic capacity. In most cases, malignant melanoma shows acquired therapy resistance. We evaluated the ability of Ocoxin, a natural compound-based antioxidant and anti-inflammatory nutritional complement, to exert an antitumor effect in melanoma. To do so, the cytotoxicity of Ocoxin in a panel of BRAF-mutated murine and human melanoma cell lines was tested alone and in combination with BRAF inhibitor Vemurafenib. Our results revealed a potent cytotoxic effect of Ocoxin against melanoma cells and a synergic effect when combined with Vemurafenib, reducing viability and increasing apoptosis. Besides, Ocoxin interferes with the cell cycle, impairs the inherent and fibroblast-mediated melanoma cell migration, and reduces resistance to BRAF inhibition. Proteomic analysis revealed reduced tumor secretion of inflammatory factors Galectin-1, Osteopontin, CCL5, and CCL9 upon treatment with Ocoxin. Moreover, RNASeq showed that Ocoxin downregulated the cell cycle and proliferation-related genes. In vivo, Ocoxin reduced the number of lung metastasis of YUMM-1.7 melanoma cells. Therefore, Ocoxin arises as a good candidate for clinical trials analyzing the beneficial effects in patients suffering from this cutaneous malignancy.This research was partly funded by Catalysis S.L

Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer

Prostate cancer is one of the most common cancers among men. Although many patients respond favorably to first-line treatments, castration—and chemotherapy—resistance arises after a few years, leading to metastasis. Thus, new approaches are being investigated using natural supplements to reinforce current therapies. Ocoxin is a plant-based mixture with antitumor properties that have been proved in several cancers. Here, we evaluated the cytotoxic capacity of this compound itself and combined with Docetaxel, Enzalutamide and Olaparib as an adjuvant agent. We observed that Ocoxin reduced tumor cell viability; slowed down cell cycles; altered the expression of genes involved in DNA replication, cell cycles and the p53 signaling pathway; and reduced migratory capacity after stimulation with cancer-associated fibroblasts (CAFs) and osteoblasts in vitro and reduced tumor volume in vivo. The combination of the nutritional supplement with chemotherapy showed a higher cytotoxic effect than chemotherapy alone and reverted chemoresistance conferred by CAFs and osteoblasts. Moreover, the adjuvant therapy also improved the outcome in vivo compared to the treatment with solo chemotherapy, where mice developed smaller tumors and less angiogenesis. Therefore, Ocoxin arises as a good candidate for further studies in combination with current treatments for prostate-cancer patients.This research was partly funded by Catalysis S.L

VII Programa General de Acción de la Unión Europea en materia de Medio Ambiente 2014-2020 y Huerta de Valencia

[EN] With this report we intend to link some of the contents of the VII General Environment Programme 2014-2020, as well as the new European Union financial instruments regulation in order to explore its posible impact on the policies in favor of actions and measures for the soil preservation of the Horta de Valencia as a peri-urban agricultural espace and as a necessary and essential matrix for a correct articulation of the green infraestructura of the metropolitana area.[ES] En esta ponencia se trata de relacionar alguno de los contenidos del VII Programa General de Medio Ambiente 2014-2020, aprobado en el contexto de la Estrategia Europa 2020, así como de la nueva regulación de los instrumentos de la Unión Europea, con el fin de explorar su posible incidencia en las políticas en favor de acciones y medidas para la preservación de los suelos de l'Horta de Valencia como espacio agrícola periurbano y como matriz necesaria y fundamental para una correcta articulación de la infraestructura verde del área metropolitana de Valencia.Montiel Márquez, A.; García De Leonardo Tobarra, E. (2015). VII Programa General de Acción de la Unión Europea en materia de Medio Ambiente 2014-2020 y Huerta de Valencia. En Irrigation, Society and Landscape. Tribute to Tom F. Glick. Editorial Universitat Politècnica de València. 1038-1053. https://doi.org/10.4995/ISL2014.2014.209OCS1038105

PROGRAMACIÓN DE LA PRODUCCIÓN EN UN AMBIENTE FLOW SHOP CON LA APLICACIÓN DE ALGORITMOS GENÉTICOS (Original)

In this work flow studies the programming of the production in an environment itself shop that has place in workshops of mechanization of pieces. In order to give answer to a problem that belongs to the area of planning, we have attended the job of her meta-heuristic Genetic Algorithms, like method of solution that offers artificial intelligence. In the programming of tasks he needs to find him an order made suitable of execution that minimizes total time of work of the machines or makespan. This problem, considered of difficult solution, is typical of the combinatorial optimization and he shows up in workshops with technology of mechanization, where there are conventional machine tools and they fabricate different kinds of pieces that have in common a same technological route (order of the process). Various problems, considering several sizes of list of works and machines got worked out and calculations that they enable developed to know the makespan's value themselves. Proofs with classical problems published by other authors came true, and we got out satisfactory results as to quality of the found solutions and the computer time.En este trabajo se estudia la programación de la producción en un ambiente flow shop que tiene lugar en talleres de mecanizado de piezas. Para dar respuesta a un problema que pertenece al área de planificación, hemos acudido al empleo de la metaheurística Algoritmos Genéticos, como método de solución que ofrece la inteligencia artificial. En la programación de tareas se precisa encontrar un orden adecuado de ejecución que minimice el tiempo total de trabajo de las máquinas o makespan. Este problema, considerado de difícil solución, es típico de la optimización combinatoria y se presenta en talleres con tecnología de mecanizado, donde existen máquinas-herramientas convencionales y se fabrican diferentes tipos de piezas que tienen en común una misma ruta tecnológica (orden del proceso). Se resolvieron diversos problemas, considerando distintos tamaños de lista de trabajos y máquinas y se desarrollaron cálculos que permiten conocer el valor del makespan. Se probó con problemas clásicos publicados por otros autores, obteniéndose resultados satisfactorios en cuanto a la calidad de las soluciones encontradas y el tiempo de cómputo

La expresión dramática como estrategia para el desarrollo de la competencia comunicativa en inglés

El proyecto de investigación aquí presentado busca fortalecer el desarrollo de la competencia comunicativa de los niños de ciclo 1 de la Institución Marco Tulio Fernández a través de la implementación de una estrategia con base en actividades que involucren técnicas de expresión dramática y la interacción entre los estudiantes mediante el uso de expresiones sencillas en inglés en contexto

Estudio biomecánico in vivo del grupo muscular flexor del codo en condiciones basales y su respuesta a la fatiga.

El objetivo del presente trabajo es establecer una aproximación al patrón de referencia habitual de la biomecánica del bíceps braquial y su respuesta a la fatiga. Sobre 37 voluntarios varones sanos se determinó una capacidad de contracción voluntaria máxima de flexión del codo de 266,8 ± 58,7N en el brazo dominante y de 258,2 ± 59,4N en el no dominante, que descendió a 211,5 ± 53N y 205,3 ± 56,5N respectivamente al someter a los voluntarios al test de fatiga (p<0,001 en ambos). El tiempo de fatiga se objetivó en 160,7 ± 72,8 s en el brazo dominante y en 156,7 ± 68,7 s en el no dominante. La supinación voluntaria máxima disminuyó de 208,7 ± 54N y 207 ± 54,8N hasta 194,1 ± 66,6N y 192,8 ± 66N respectivamente en el estudio postfatiga (p<0,001 en ambas). No se apreciaron diferencias significativas en el estudio de subgrupos por edades

DISEÑO E IMPLEMENTACIÓN DE UN HEXÁPODO ROBÓTICO EMPLEANDO EL DRIVER “INTECMX14” PARA EL CONTROL PARALELO DE MOTORES

ResumenLos robots móviles por sus características requieren de estructuras estables y sistemas de control con las capacidades para lograr movimientos fluidos o naturales, proyecto propone un hexápodo con tres grados de libertad construido a base del uso de nylalloy como material principal, utilizando 18 servomotores distribuidos en juegos 3 por cada extremidad, con uso de una tarjeta FPGA atlys para el desarrollo de una programación paralela dentro de 4 rutinas de movimiento diferentes cuyas posiciones fueron calculadas por el método de cinemática de Denavit-Hartenberg y el método inverso haciendo uso de matrices Homogénea.Palabras clave: Denavit-Hartenberg, Hexápodo, Robot móvil. DESIGN AND IMPLEMENTATION OF A ROBOTIC HEXAPOD USING THE "INTECMX14" DRIVER FOR PARALLEL MOTOR CONTROL AbstractMobile robots by their characteristics require stable structures and control systems with the capabilities to achieve fluid or natural movements, proposes a game with three degrees of freedom built using nylalloy as the main material, using 18 servomotors distributed in games 3 for each tip, using an atlys FPGA card for the development of parallel programming within 4 different motion routines whose positions were calculated by the Denavit-Hartenberg direct kinematics method and the inverse method with the use of homogeneous matrix.Keywords: Denavit-Hartenberg, Hexapod, mobile robot

Experience with the ACURATE neo and neo2 transcatheter aortic valves in Spain. The PRECISA (PRospective Evaluation Complementing Investigation with ACURATE devices) registry

Transcatheter aortic valves; SpainVàlvules aòrtiques transcatèter; EspanyaVálvulas aórticas transcatéter; EspañaBackground Previous studies have documented a high rate of implantation success with the ACURATE neo2 valve, as well as a reduction in paravalvular leak (PVL) compared to its predecessor, the ACURATE neo. However, there are no studies that have reviewed and compared the long-term clinical and hemodynamic outcomes of these patients. Aims This study aimed to evaluate the results of the ACURATE neo transcatheter aortic valve in a real-world context, and to compare the results of the outcomes of both generations of this device (ACURATE neo and ACURATE neo2), with a specific focus on procedural success, safety, and long-term effectiveness. Methods A prospective study including all consecutive patients treated with the ACURATE neo device in seven hospitals was conducted (Clinical Trials Identification Number: NCT03846557). The primary endpoint consisted of a composite of adverse events, including mortality, aortic insufficiency, and other procedural complications. As the second-generation device (ACURATE neo2) replaced the ACURATE neo during the study period, hemodynamic and clinical results before admission, at 30 days, and at 1 year of follow-up were compared between the two generations. Results A total of 296 patients underwent transcatheter aortic valve implantation with the ACURATE device, with 178 patients receiving the ACURATE neo and 118 patients receiving the ACURATE neo2. In the overall population, the absence of device success occurred in 14.5%. The primary reason for the absence of device success was the presence of para-valvular regurgitation ≥ 2. There were no instances of coronary occlusions, valve embolization, annulus rupture, or procedural deaths. ACURATE neo2 was associated with a significantly higher device success rate (91.7% vs. 82%, p = 0.04), primarily due to a significantly lower rate of para-valvular regurgitation, which remained significant at 1 year. Conclusion The use of ACURATE neo and neo2 transcatheter aortic valves is associated with satisfactory clinical results and an extremely low rate of complications. The ACURATE neo2 enables a significantly higher device success rate, primarily attributed to a significant reduction in the rate of PVL